Stock Analiz

Haemonetics Corp. (HAE) stock forecast and price target

Price $122.94 · data as of November 13, 2026

12-month price target

Average target$144.55
Upside / downside+17.6%
Analysts11
ConsensusBuy
Low $115.00Average $144.55High $165.00

Gold marker: average target · white marker: today’s price ($122.94)

Analyst ratings

Strong buy 4Buy 6Hold 2Sell 0Strong sell 0

Earnings and revenue estimates

PeriodEPS estimateEPS growthRevenue estimate
Current fiscal year
ends March 31, 2027
$5.34+7.7%$1.4B
Next fiscal year
ends March 31, 2028
$6.20+16.1%$1.6B
Next quarter
ends December 31, 2026
$1.27−2.8%$358M
Quarter after
ends March 31, 2027
$1.58+22.6%$388M

Consensus of the analysts covering Haemonetics, updated daily. In the last 30 days 3 estimates were raised and 2 lowered.

Our model vs. Wall Street

Analysts see 17.6% upside over 12 months. Our discounted cash flow model with moderate assumptions puts Haemonetics’s intrinsic value about 37% below today’s market value, and it scores 1.8 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.

Frequently asked questions

What is the Haemonetics stock price target?

The average 12-month target from 11 analysts is $144.55, 17.6% above the current price of $122.94 Targets range from $115.00 to $165.00.

Is Haemonetics a buy according to analysts?

The consensus rating is “Buy” (4 strong buy, 6 buy, 2 hold). Ratings are opinions, not guarantees; this is not investment advice.

How much is Haemonetics expected to earn?

Analysts expect EPS of $5.34 for the fiscal year ending March 31, 2027 and $6.20 the year after.

Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.